The use of homeopathic medicines as part of a self-care solution to treat such ailments as the common cold or back pain is becoming more commonplace through conventional channels, with sales generating $392.9 million, up 3.3%, as compared to $58.1 million on 0.9% growth in natural channels for the 52 weeks ended July 10.
Quest Products is looking to break onto the external analgesic scene with CopperFixx, a balm that combines the analgesic properties associated with copper and arnica. Other brands continuing to lead the way were Blue Emu ($28.6 million, up 20.1%), Australian Dream ($23.1 million, up 20.7%) and Boiron’s Arincare ($19.1 million, up 19.7%).
Pfizer’s Nexium 24HR is the clear leader in the digestive aisle. However, in March 2017, store-brand versions of Nexium 24HR will be available. Perrigo has already secured a tentative approval from the Food and Drug Administration for its OTC Nexium 24HR generic equivalent.
Consumers with diabetes spend 35% more on OTC products than the average consumer, noted Jeff Gregori, group VP consumer and shopper analytics for Nielsen, during a recent presentation at the National Association of Chain Drug Stores Total Store Expo. Sales of product with a diabetes-specific focus increased 5.1% in 2015, according to Nielsen, reaching $592 million in total sales.